chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Headache, Myalgia, Arthralgia, Rash, UrticariaPruritus, Diarrhea,  SWELLING TO THEW RIGHT BREAST AND GENERALIZED SWELLING OF FACE, TENDERNESS TO THE INJECTION SITE  Narrative:  TOOK EPIPEN HAD AT HOME FOR OTHER RELATED ALLERGIES DID NOT SEEK MEDICAL CARE
Huge rash, infection from shoulder to under elbow on right arm. Patient was given KEFLEX 500 TID.
After my vaccination I developed a lump under my left arm and both glands in my neck had swelled up as well. They had general soreness and pain, however, under my arm it lasted for weeks until it went away. My neck gland swelling went down in a few days. Now there is no longer any swelling going on. October 17th 2022, I came down with severe COVID-19 symptoms and went to a doctor's office and they sent me home to take an at home test. For the at home test it came out positive and they prescribed me an antiviral, PAXLOVID, and a steroid for seven days. As of now I am feeling much better and I believe the PAXLOVID helped out tremendously. However, a major issue I am having is fatigue and my face is still numb, My taste buds are also slightly off. Suddenly I have developed a body shake or trembling that occurs randomly.
Pt is a 22 yo M who was getting second dose of Moderna vaccine. Afterward pt started to feel mildly itchy, lightheaded, and had some chest tightness and mild SOB. SpO2 was 97%, and HR was 88. Pt had not issues with the first vaccine.  Evaluated pt in the Immunizations clinic. Do not believe that pt is having an anaphylactic reaction to the vaccine, however, may be having some kind of adverse reaction. ECG was normal and shows no signs of myocarditis. However, myocarditis can present itself 1-2 weeks after the vaccine. Told pt to go to ED if sx significantly worsen and that he can take some time off from work. When he returns to work he should be on LD until his sx completely resolve. Told pt to return to the clinic if they do not.
This infant developed hives all over his body, erythema multiforme 1 day after his vaccination. The patient is on Augmentin for 1 week, also treatment for periorbital cellulitis. Oral steroid started and Augmentin.
Patient given bivalent booster when should have received the monovalent primary dose. No adverse effects known.  Error caught when patient returned for second dose in primary series. Recommendations reviewed and patient given monovalent dose for second dose in primary series.
Patient fainted, became limp so we checked for pulse and held her head up, she began foaming saliva and choked on it, and began seizing for about 5 seconds then came to.  Patient declined EMS
This case was reported by a physician via sales rep and described the occurrence of white blood cell count increased in a patient who received BEXSERO. Co-suspect products included BEXSERO. On an unknown date, the patient received the 1st dose of BEXSERO and the 2nd dose of BEXSERO. On an unknown date, unknown after received BEXSERO and not applicable after receiving BEXSERO, the patient experienced white blood cell count increased, fever, white blood cell count increased and fever. The patient was treated with antibiotics. On an unknown date, the outcome of the white blood cell count increased and fever were recovered/resolved and the outcome of the white blood cell count increased and fever were unknown. It was unknown if the reporter considered the white blood cell count increased and fever to be related to BEXSERO. It was unknown if the reporter considered the white blood cell count increased and fever to be related to BEXSERO. Additional details were reported as follows: The age at vaccination was not reported. The sales representative did not know the age of this specific patient but said the reporter was immunizing 16 to 18 years old patients. Recently the patient experienced an elevated white blood count and a fever of 104 degree F. The physician prescribed antibiotics and the symptoms resolved. The events recurrent after 2nd dose of BEXSERO.
Itching at vaccination site then led to redness and inflammation  around the area about the size of a baseball within 24 hours.  Had itching on other parts of body, i.e arms, head, legs..  Took Benadryl and initially did not help itching or redness at vaccination site.  After 24-36 hours itching began to decrease but redness and inflammation remained.
Grandmother present for shots.  States he was cryig for the shots, wimpered a little after, eyes rolled back than immediately fell asleep.  Unable to wake for 3 hours.  Called doctor.  Parents took to Hospital.  No episodes of cyanosis or apnea.  Pt. admitted for overnight observation - no further episodes noted.  Discharge doctor wanted this event reported. 1/10/08-records received for DOS 10/19-12/20/08-admitted for observation-C/O eyes rolled back and passed out. About a minute after the shots when the patient had stopped crying he had an episode where the eyes rolled back and then he passed out and was unresponsive for an hour. No skaking no loss of tone. Did not respond to attempts to waken. No cyanosis and no apnea. Sleepy. DX: hypotonic hyporesponsive episode.
Information has been received from a physician concerning a 9 year old male who on 26-Jan-1998, was vaccinated with a dose of Varivax. Subsequently, on 16-May-2006 the patient experienced a "mild" case of breakthrough varicella rash. Unspecified medical attention was sought. No further information available. There was no product quality complaint involved. Additional information received indicated that there was no further information available. No additional information is expected.
Patient came in for her second dose of shingrix vaccine. Her husband assisted her walking in as she does have mobility issues. After the vaccine patient felt weak, but with the assistance of her husband went home. The next morning patient felt her legs were getting weaker and she even slipped off the toilet. 911 was called, EMT checked her BP and Mental status which checked out okay. She later did go to the emergency room and was admitted. Per patient nothing has been determined, but she is being referred to rehab/PT to build strength.
09/14/12 Fri am stiff all over - noon - pain increased, all joints and to jaw, bed bound - rocking, rolling movement to help pain lessen. ER Fri night 2pm, test, blood work, morphine, TORADOL PHENERGAN. Home with VICODIN, muscle relaxant ROTAXIN to home q 4 hours x 2 days Sat, Sun. Monday am feel better back to work.
About 15 minutes after receiving vaccine, patient started to have chest pain and high blood pressure. Her blood pressure was 170/110 at 2:30 and then at 2:40 it was 130/110. She was feeling better and pulse was good around 2:45pm. She did take a Benadryl that was offered. She was not having any trouble breathing or dizziness. Patient went by EMS to get checked out and was cleared by the hospital staff.
Platelet count was 52,000/his count was 47,000/his count was down to 16,000; This spontaneous case was received on 15-Dec-2021 from other non-healthcare professional (patient's wife) via Agency (reference number: SEQW21-06152) and concerned an adult male patient.  The patient's concurrent conditions included diabetes and low blood pressure. The patient's concomitant medications included Januvia (sitagliptin phosphate), metformin, Jardiance (empagliflozin) and Paxil (paroxetine hydrochloride), all used for an unreported indication.   On 22-Sep-2021, the patient was vaccinated with Fluad Quadrivalent (influenza vaccine, inactivated influenza virus surface antigen (subunit), egg-derived, mf59; dose: 0.5 ml, route of administration and anatomical location: not reported) for influenza prophylaxis. The batch number was not reported.  On an unspecified date in Oct-2021, reported as two weeks after receiving Fluad Quadrivalent, the patient went to his endocrinologist and his platelet count was 52,000.   On an unknown date in 2021, unknown amount of time after receiving Fluad Quadrivalent, the patient went to his primary care physician and his count was 47,000. He was then seen by a haematologist and his count was down to 16,000. The physicians were working together and had taken him off of Jardiance. He was given Promacta (eltrombopag olamine) for a week which did not help. Then they tried with prednisone for a week which also didn't help. The patient had a bone marrow biopsy and saw a second haematologist, who wanted to schedule a second bone marrow biopsy.   At the time of initial reporting on 15-Dec-2021, the patient had not recovered from the event.   The reporter did not provide causality assessment.   The case was assessed as non-serious.  Company comment: A patient of unknown age developed decreased platelet count an unknown amount of time after receiving the suspect product Fluad Quadrivalent. Due to unclear time relationship, causality is unassessable.; Sender's Comments: A patient of unknown age developed decreased platelet count an unknown amount of time after receiving the suspect product Fluad Quadrivalent. Due to unclear time relationship, causality is unassessable.
Patient received Moderna COVID vaccine at a health dept clinic in February and experienced blurred vision and 3 weeks of fever afterward.  CDC consulted and the recommendation was to use Janssen COVID vaccine as second dose with monitoring for 30 minutes. Allergist agreed. After Janssen vaccine, patient was fine for first 28 minutes, then experienced blurred vision, light-headedness. At 10:10 patient became palor and lost consciousness. EpiPen given and patient immediately responded.  EMS called and 50 mg IM diphenhydramine given. No SOB, wheezing, or CP. Positive for palpitations
About 1.5 hours following the administration of the second dose of the vaccine, I developed hives, pruritis, and erythema on both arms, torso, and neck. I also experienced headache, nausea, and leg muscle cramping/weakness.
Received a second dose of menveo by mistake; This case was reported by a nurse via call center representative and described the occurrence of extra dose administered in a 18-year-old female patient who received Men ACWY-CRM NVS (Menveo) (batch number AMVA7222V, expiry date 31st August 2023) for prophylaxis.   On 5th August 2022, the patient received Menveo. On 5th August 2022, unknown after receiving Menveo, the patient experienced extra dose administered. On an unknown date, the outcome of the extra dose administered was unknown.   Additional Information: GSK receipt date: 12-Aug-2022 Reporter comment: A nurse reported that the patient received a second dose of Menveo by mistake. The reporter consented to follow up. Additional supportive information: The patient received second dose of Menveo, which led to extra dose administrated.
This spontaneous case was reported by a physician and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) and PRODUCT ADMINISTRATION ERROR (Product administration error) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 038B21A) for COVID-19 vaccination.No Medical History information was reported.On 08-Oct-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 08-Oct-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) and PRODUCT ADMINISTRATION ERROR (Product administration error). On 08-Oct-2021, EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) and PRODUCT ADMINISTRATION ERROR (Product administration error) had resolved. Not Provided.For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.No concomitant medications were provided by the reporter. No treatment medications were provided by the reporter.
This spontaneous report as received from a medical assistant (M.A.) refers to unspecified number of patients of unknown age and gender. On an unknown date, the patients were vaccinated with improperly stored doses of M-M-R II (lot# reported as K014833, expiration date 14-SEP-2016, dose, frequency and route of administration were not reported). No adverse events were reported. Product quality complaint (PQC) was not involved. Additional information is not expected due to lack of physician's contact details.
GBS, numbness, unable to swallow, unable to walk or speak, move, paralysis, pain, unstable blood pressure, complication from ventilation tube, on ventilator two times, multiple tests, rehabilitation in hospital, physical therapy, lumbar puncture, cat scan, MRI, EMG, lab, blood work.
Red, warm, raised rash at injection site.  Tenderness/soreness returned to arm in the day preceding the rash.
PATIENT GOT THE SECOND DOSE AND TOLD TO HAVE A SEAT FOR ABOUT 15 MINUTES FOR POST-VACCINE SURVEILLANCE. HE STOOD UP FROM A SITTING POSITION AND APPROACHED THE PHARMACY COUNTER, THAT'S WHEN HE COLLASPED HEAD-FIRST IN THE LOBBY. WE IMMEDIATELY CALLED 911, EMS, AND HIS FATHER. HE WAS HELP AND REGAIN CONSCIOUSNESS WITH ORANGE JUICE, PRETZELS, AND WATER. EMS CAME TO CHECK HIS VITALS AND HIS BLOOD SUAGRS WAS IN THE LOW 70S, ABOUT 73. HE STATES HE DID NOT EAT ANYTHING ALL DAY. EMS ALSO FOUND THAT HIS HEARTBEAT WAS IRREGULAR AND THEN PATIENT CONFIRMS THAT HE MIGHT HAVE AN IRREGULAR HEART BEAT BUT HAS NOT BE DIAGNOSED. PATIENT FAILED TO MENTION THAT ON HIS VACCINATION ADMINISTRATION RECORD FORM WHICH WE USE TO  HELP DETERMINE PATIENT ELIGIBILITY FOR THE VACCINE TODAY.
Rash on legs, fever 103.5, lethargic and not acting normal.
shingles (Herpes Zoster); blisters; Rash; Nerve pinch and pain; Nerve pain; exhausted; This spontaneous case was reported by a consumer and describes the occurrence of HERPES ZOSTER (shingles (Herpes Zoster)), NERVE COMPRESSION (Nerve pinch and pain), NEURALGIA (Nerve pain), BLISTER (blisters) and RASH (Rash) in a 49-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 021C21A and 030B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concomitant products included ACYCLOVIR [ACICLOVIR] for Shingles.   On 04-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 01-May-2021, the patient experienced FATIGUE (exhausted). On 22-May-2021, the patient experienced NERVE COMPRESSION (Nerve pinch and pain) and NEURALGIA (Nerve pain). On 26-May-2021, the patient experienced BLISTER (blisters) and RASH (Rash). On 29-May-2021, the patient experienced HERPES ZOSTER (shingles (Herpes Zoster)). The patient was treated with CALAMINE, GLYCEROL, ZINC OXIDE (CALAMINE LOTION) for Blisters, at an unspecified dose and frequency; GABAPENTIN for Adverse event, at a dose of 300mg and PARACETAMOL (TYLENOL) (oral) for Adverse event, at a dose of 500 milligram. At the time of the report, HERPES ZOSTER (shingles (Herpes Zoster)), NERVE COMPRESSION (Nerve pinch and pain), NEURALGIA (Nerve pain), BLISTER (blisters), RASH (Rash) and FATIGUE (exhausted) outcome was unknown.
Chronic plaque psoriasis flare up; This spontaneous case was reported by a consumer and describes the occurrence of PSORIASIS (Chronic plaque psoriasis flare up) in an adult female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product RISANKIZUMAB (SKYRIZI [RISANKIZUMAB]) for Plaque psoriasis.    No Medical History information was reported.   On 11-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 08-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started RISANKIZUMAB (SKYRIZI [RISANKIZUMAB]) (unknown route) at an unspecified dose. On an unknown date, the patient experienced PSORIASIS (Chronic plaque psoriasis flare up). At the time of the report, PSORIASIS (Chronic plaque psoriasis flare up) had not resolved.            It was unknown if patient was enrolled in a COVID-19 Vaccine Trial. No concomitant medications were reported. No treatment medications were reported.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.
pale in color, p/receiving Td vax, went from chair to floor, remains consscious throughout the entire ordeal; rested on floor 5 mins;
Right ankle/foot swelling the day following vaccination. No redness, tenderness, or itching. The reaction only lasted 24 hours from vaccine.
loss of appetite; headaches; stomach ache; This spontaneous case was reported by a consumer and describes the occurrence of DECREASED APPETITE (loss of appetite), HEADACHE (headaches) and ABDOMINAL PAIN UPPER (stomach ache) in a 77-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 026A21A and 032B21A) for COVID-19 vaccination.     The patient's past medical history included No adverse event.   On 05-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 02-Apr-2021, the patient experienced DECREASED APPETITE (loss of appetite), HEADACHE (headaches) and ABDOMINAL PAIN UPPER (stomach ache). On 13-Apr-2021, DECREASED APPETITE (loss of appetite), HEADACHE (headaches) and ABDOMINAL PAIN UPPER (stomach ache) had resolved.          Patient has used ibuprofen, Pepto Bismol,, BRAT diet, and turmeric tea.   Reporter did not allow further contact
Suspected vaccination failure/My sister got the shingles vax and got shingles; My sister got the shingles vax and got shingles; This case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a female patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   The patient's past medical history included shingles (Family History) (unvaccinated brother-in-law had shingles ).   On an unknown date, the patient received Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. On an unknown date, the outcome of the vaccination failure and shingles were unknown.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine.     Additional Information: GSK receipt date: 4-Aug-2022 Reporter's comment: The case was received from the patient's sister via interactive digital media. The patient got the shingles vaccine and both she and reporter's unvaccinated husband (patient's brother-in-law) got shingles. Additional supportive information: This case was considered as suspected vaccination failure since the details regarding the completion of primary vaccination schedule, time to onset and laboratory confirmation of shingles were unknown at the time of reporting. The follow-up could not be possible as no contact details were available.
This spontaneous report was received from a physician via company representatives and from a support services director concerning to a patient of unknown age and gender. Information about the patient's pertinent medical history, concurrent conditions, drug reactions/allergies and concomitant medications was not reported. On 23-DEC-2014, the patient was vaccinated with an improperly stored dose of PNEUMOVAX 23 which had the lot # K009874 with expiration date 19-MAR-2016 (dosage number and route of administration were not reported). On an unspecified date, the vaccine had a temperature excursion for 24 hours in which the lowest recorded temperature was 34 degrees Fahrenheit (1.111111111 degrees Celsius). The vaccine status was reported as "in excursion". The vaccine storage criteria and type were reported as "refrigerator (R)". No adverse effects were reported and no product quality complaint was involved. This is one of the several reports received from the same reporter. Additional information has been requested.
Patient was given 0.5ml dose of Moderna for booster instead of 0.25ml
Raised bumps on right leg and cheek, diarrhea 24 hours later, bumps lasted 4 days.
Rash, blotchy, red on face, scalp, back, stomach and diaper area.
10 days p/vax (23MAR92) went to MD, dx: measles; 1 wk later (28MAR92) back to MD w/enlarged lymph nodes; mom described "knots-where you get the mumps-the size of walnuts"; given ATBs ESP-BARR & recovered;
Immediate (4/26) redness and swelling at injection site (approximately 2 inches in diameter), pain at injection site, and warm to touch Within 24 hours (4/27) the redness and swelling increased (about doubled in size), discomfort in the area, and warm to touch 4/28 redness and swelling slightly larger, still warm to touch - returned to the Doctor's office and was perscribed an antibiotic and instructed to watch for changes
3" diameter rash at the injection site 10 days after the injection that was hot to the touch and itchy; 3" diameter rash at the injection site 10 days after the injection that was hot to the touch and itchy; 3" diameter rash at the injection site 10 days after the injection that was hot to the touch and itchy; This is a spontaneous report from a contactable consumer. An elderly male patient received BNT162B2 (BNT162B2, solution for injection), dose unknown via an unspecified route of administration on 01Feb2021, as dose number unknown single (Batch/Lot number was not reported Expiry date was not reported), for COVID-19 immunisation. The patient's medical history and concomitant medications was not reported. Patient (friend's father) experienced a 3" diameter rash at the injection site 10 days after the injection that was hot to the touch and itchy. It was unknown whether patient had covid prior vaccination or post vaccination. It was unknown whether patient had received treatment for the events. The outcome of events was recovering.   No follow-up attempts are possible; information about lot/batch number cannot be obtained.
CAN NOT MOVE LEFT ARM; This spontaneous report received from a patient via a company representative concerned a male of unspecified age. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were not reported) dose was not reported, administered on JUN-2021 for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported.  On an unspecified date, the patient experienced can not move left arm. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from can not move left arm. This report was non-serious.
I experienced chills to the point I felt hypothermic, and was unable to get warm with multiple layers of blankets and the heat turned up. I was extremely fatigued as well, and I could not physically leave the bed to go see my doctor in person. My temperature was 95.2 degrees Fahrenheit, every bone in my body ached, my sense of smell is muted, I was sweating profusely, completely incapacitated, and it took me 2 weeks to recover. I'm still experiencing fatigue, my sense of smell is muted, body aches.